IL17A and myeloid sarcoma: Moreover, pathogenic cytokines (IFN-γ, IL-17, TNF-α, IL-6, IL-12p70, and IL-10) can also reflect the degree of inflammation in patients, as MS therapies are largely aimed at lowering the inflammatory response by modulating the levels of inflammatory markers [39].